Real‐World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large‐Scale Post‑Marketing Surveillance Study

Documenti analoghi

• Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors
  di: Midori Shima, et al.
  Pubblicazione: (2025)
• Dental Management of Persons With Haemophilia Receiving Emicizumab Prophylaxis
  di: Branislav V. Bajkin, et al.
  Pubblicazione: (2026)
• Real‐World Data on Patients With Acquired Haemophilia A in Japan Undergoing Rehabilitation or With Low Activities of Daily Living Scores: The ORIHIME II Study
  di: Yoshiyuki Ogawa, et al.
  Pubblicazione: (2024)
• Reduced‐Dose versus Standard‐Dose Emicizumab for Haemophilia A: A Retrospective Cohort Study
  di: Huiling Yan, et al.
  Pubblicazione: (2025)
• Outcomes of Emicizumab Treatment for Haemophilia A Paediatric Patients: A Systematic Review With Meta‐Analysis
  di: Konstantina Bolou, et al.
  Pubblicazione: (2025)